Načítá se...
Acute hypertension during ramucirumab infusion in two patients with advanced oesophagogastric cancer
Ramucirumab, a monoclonal antibody targeting the vascular endothelial growth factor (VEGF) pathway, in combination with paclitaxel is becoming part of standard second-line systemic therapy for advanced oesophagogastric cancer, based on the results of the REGARD and RAINBOW trials. Common well-known...
Uloženo v:
| Vydáno v: | BMJ Case Rep |
|---|---|
| Hlavní autoři: | , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMJ Publishing Group
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5015152/ https://ncbi.nlm.nih.gov/pubmed/27539134 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bcr-2016-215801 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|